Primary Job Title Co-Founder Primary Organization 
Otologic Pharmaceutics
Location Oklahoma City, Oklahoma, United States Regions Southern US Gender Male
LinkedIn View on LinkedIn
Robert Floyd, PhD has conducted NIH-funded basic biomedical research for over 35 years at the Oklahoma Medical Research Foundation (OMRF). For 20 years he was head of the Free Radical Biology and Aging Research department and helped to recruit several highly accomplished scientists in this field of research to the OMRF and the Oklahoma University
Health Sciences Center. He is considered an international expert on the role of free radicals and reactive oxygen species in age related diseases and has won several awards including the Glenn Foundation for medical Research Award (1992), Top Award and Gold Medal of the American Aging Association (1996) and The Discovery Award of the Society for Free Radical Biology and Medicine (2007).
He has pioneered in patented discoveries and translational science on the use of nitrones as therapeutics for the treatment of ischemic stroke as well as anti-cancer agents. This research resulted in collaboration efforts leading to the founding of Centaur Pharmaceuticals (1992) and Onconos LLC respectively. In the 8 yr history of Centaur Pharmaceuticals he served as a member of the Board of Directors and Chairman of the Scientific Advisory Board of this biotech company which partnered with AstraZeneca to develop NXY-059 for the treatment of stroke that underwent extensive phase I, II and III clinical trials. Over the last 5 years, he and Dr. Rick Kopke have collaborated in the development of the use of antioxidants for the treatment of noise-induced hearing loss in animal models. Their research has led to the discovery that specific nitrones and NAC act synergistically to prevent noise-induced hearing loss. These patented discoveries have helped lead to the founding of Otologic Pharmaceutics, Inc.
